NHSE Interim treatment options

Message from Steve Williamson, NHS England Lead Cancer Pharmacist

29th April 2020 – NHSE Interim treatment options

 

Dear Colleague

You may have seen that NICE has published an updated table to the SACT clinical guideline NG161 listing many new Interim treatment options earlier this week. See https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381. There are a couple of points of clarification for providers to note:

  • Enzalutamide for prostate cancer states it is subject to confirmation, we can confirm enzalutamide is approved, and there is no need to check for confirmation. A Blueteq form for abiraterone for patients unable to tolerate enzalutamide will be made available in due course.
  • Gilteritinib is approved for relapsed /refractory AML and not newly diagnosed AML.
  • Nivolumab is approved in MSI-H colorectal cancer, the wording states ‘subject to confirmation’ we can confirm this is approved and there is no need to check for confirmation.
  • A blueteq form for polatuzumab will be released in due course as NHSE is currently working with the company to ensure there is stock available for the selected patient group.

We advise all these indications are to be billed through the usual specialised commissioning route, as there is additional COVID19 funding available for them.  Any drugs where we have changed the CDF pathway are not funded through CDF as there is separate COVID19 funding for them. We are pleased to note that the manufacturers of many of these drugs have worked with NHS England and offered additional discounts to support the NHS during COVID19.

Latest News

By BOPA on 15th February 2025

Join us at the Clinical Pharmacy Congress 2025 🗓️

BOPA are proud to announce our partnership with Clinical Pharmacy Congress London 2025, the UK’s largest bi-annual gathering of pharmacy professionals taking place for the 14th time on 9-10 May 2025, at Excel…

Read article
By BOPA on 14th February 2025

BOPA Collaboration Webinar – Highlights from COSA ASM 2024

Wednesday 26th February 2025 at 21:00 GMT (27th Feb 07:00 ASET or 26th Feb 14:00 Canadian MST) Click HERE to register (For COSA CPG members click here, CAPhO members click…

Read article
By BOPA Committee on 14th February 2025

UK BMT Pharmacists’ Group – Educational Meeting 28th Feb 2025

The UK BMT Pharmacists’ Group (a special-interest group affiliated to BOPA) is running an educational meeting via Zoom on the afternoon of Friday 28th February 2025. The meeting will run…

Read article
By BOPA E&T Subcommittee on 12th February 2025

The BOPA Cancer Consultant Pharmacist Credentialing Support Series is back

BOPA are holding a nine-month supportive webinar series for pharmacists who are credentialing as consultant pharmacists with the RPS. First session: Wednesday 26th February 12:30pm Join in this relaxed forum…

Read article